Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine for prevention of colistin-induced nephrotoxicity
IRCT20200328046886N5Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in colistin-induced nephrotoxicity comparing N-acetylcysteine + colistin with Placebo + colistin (2 arms). Primary endpoints: Urinary N-acetyl-beta-D-glucosaminidase level and Renal function change by RIFLE criteria. Started Oct 2023; status: completed.
02
Drugs
acetylcysteine
03
Conditions
colistin-induced nephrotoxicity
Beyond the preview
Go deeper on IRCT20200328046886N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200328046886N5.